Company news
SanBio Co., Ltd. news in 2022
SanBio Co., Ltd.'s news releases, calls and decks from 2022, newest first.
Announcement on Granting Stock Options (Share Acquisition Rights)
August 16, 2022
Notice regarding appointment of new corporate officers
August 1, 2022
Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
July 22, 2022
Keizo Nakada to Join SanBio as Corporate Officer and Head of Production
July 1, 2022
Recording of Non-operating Income (Foreign Exchange Gains), Deferred Income Taxes, and Short-Term Loans Payable
June 15, 2022
SanBio: Consolidated Financial Results for the Three Months Ended April 30, 2022
June 14, 2022
Andrew Liu to Join SanBio as Chief Strategy Officer
June 1, 2022
SB623 Demonstrated Sustained Improvement in Motor Impairment up to 48 Weeks and Associated with Improvement
April 5, 2022
SB623 Demonstrated Sustained Improvement in Motor Impairment up to 48 Weeks and Associated with Improvement in Function and Activities of Daily Living in Patients with Chronic Traumatic Brain Injury
April 5, 2022
［Delayed］Recording of Non-Operating Expenses (Financing Expenses)
March 23, 2022
Partial Amendment to the Articles of Incorporation, Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Capital Surplus
March 11, 2022
SanBio: Announcement on Issuance Plans of Stock Options (Share Acquisition Rights)
March 11, 2022
Presentation for Financial Results for the Fiscal Year Ending Jan.31, 2022
March 11, 2022
SanBio: Consolidated Financial Results for the Fiscal Year Ended January 31, 2022
March 11, 2022
SanBio: Notice Regarding Completion of Approval Filing for Japan SB623 Chronic TBI Program
March 7, 2022
Notice regarding completion of approval filing for Japan SB623 chronic TBI program
March 7, 2022